RLAY Earnings Date: Nov 5, 2026 (Estimated) — Relay Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is RLAY's next earnings date?
Relay Therapeutics, Inc. (RLAY) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.40 on revenue of $1.6M.
How did RLAY do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Relay Therapeutics, Inc. posted EPS of -$0.41 versus the -$0.39 estimate, a miss of 2.5%. Revenue was $350,000 against a $960,000 estimate. The stock's 1-day post-earnings move was +0.1%.
How much does RLAY stock move after earnings?
RLAY beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.4% (up or down) in the day after earnings.
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.39 | -0.41 | -2.50% | $350,000 | ❌ Miss | +0.10% | +0.91% | -3.59% |
| 2026-05-05 | Q1 2026 | -0.36 | -0.41 | -13.89% | $3.0M | ❌ Miss | -0.62% | -0.54% | +11.85% |
| 2026-02-26 | Q4 2025 | -0.39 | -0.32 | +17.95% | $7.0M | ✅ Beat | +12.01% | +5.24% | +4.80% |
| 2025-11-06 | Q3 2025 | -0.41 | -0.43 | -4.88% | $0 | ❌ Miss | -7.35% | -1.23% | +16.85% |
| 2025-08-07 | Q2 2025 | -0.48 | -0.41 | +14.58% | $677,000 | ✅ Beat | -7.74% | -2.87% | +16.33% |
| 2025-02-26 | Q4 2024 | -0.55 | -0.45 | +18.18% | $0 | ✅ Beat | -13.33% | -9.60% | -20.27% |
| 2024-11-06 | Q3 2024 | -0.77 | -0.63 | +18.18% | $0 | ✅ Beat | -1.76% | -7.04% | -26.24% |
| 2024-08-06 | Q2 2024 | -0.73 | -0.69 | +5.48% | $0 | ✅ Beat | -7.93% | -8.76% | -9.74% |
Showing last 8 quarters.